Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.55 |
| ▸ | CA2 | P00918 | 8/20 | 0.55 |
| ▸ | CA12 | O43570 | 7/20 | 0.55 |
| ▸ | CA7 | P43166 | 7/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 0.55 |
| ▸ | CA9 | Q16790 | 6/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.46 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.40 |
| ▸ | APOB | P04114 | 1/20 | 0.39 |
| ▸ | MTTP | P55157 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5738668 | 1.00 | CA1 (0.55) | CA1CA2CA12CA7CA14 | |
| SCHEMBL5738672 | 1.00 | CA1 (0.55) | CA1CA2CA12CA7CA14 | |
| SCHEMBL5740874 | 0.86 | CA1 (0.57) | CA1CA2CA12CA7CA14 | |
| SCHEMBL5739726 | 0.86 | CA1 (0.57) | CA1CA2CA12CA7CA14 | |
| SCHEMBL5739723 | 0.86 | CA1 (0.57) | CA1CA2CA12CA7CA14 | |
| SCHEMBL5738299 | 0.85 | GRM7 (0.44) | CA1CA2CA12CA7CA14 | |
| SCHEMBL5738304 | 0.85 | GRM7 (0.44) | CA1CA2CA12CA7CA14 | |
| SCHEMBL5739354 | 0.85 | GRM7 (0.44) | CA1CA2CA12CA7CA14 | |
| SCHEMBL5739213 | 0.84 | CA1 (0.59) | CA1CA2CA12CA7CA14 | |
| SCHEMBL5738563 | 0.84 | CA1 (0.59) | CA1CA2CA12CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697334-A1 | HETEROCYCLIC SUBSTITUTED INDANE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050282819-A1 | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia | GRAHAM JAMES M | 2005-12-22 | — | — | US | disclosed |
| WO-2005056540-A1 | HETEROCYCLIC SUBSTITUTED INDANE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282819-A1 | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia | CHRM1, CHRM2, CHRM5 | CA1 3909/4885CA2 4660/4885CA12 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.